The V Commemorative Lecture Clara Pitched analyzes the latest developments for a personalized approach to colorectal cancer.
Recent advances aimed at achieving an earlier diagnosis, optimal treatment and proper monitoring of colorectal cancer and a more personalized approach and disease management focused conferences of the V Commemorative Lecture Pitched Clara, held in June in HMS- CIOCC.
As in addressing other malignancies, these are also the objectives of CIOCC in the case of colorectal cancer, as explained by its director, Dr. Manuel Hidalgo. "Our organization, comprehensive, multidisciplinary, is more horizontal than vertical, and her treatment of patients is done through cross-cancer programs," he said, stressing the "pioneer project" that represents the combination of clinical care, teaching and research done in HM hospitals, and of course in the CIOCC, in which "the center of all activity is the patient, and gravitate around him all the specialists, technologies and initiatives aimed at a more favorable development of its disease".
Robotic surgery, spoken of by Dr. Emilio Vicente, director of the Department of General Surgery and Digestive HMS also provides important advantages in the approach of colorectal cancer, and used up to 17% of patients with rectal cancer HM Hospitals successfully without surgical complications.
For his part, Dr. Alain Huerta, of the Gastroenterology Endoscopy-HMS, said that prevention is effective in colorectal cancer because it can recudir the incidence or allow an early diagnosis, thus changing the natural history of this tumor, because when caught early it can be cured in 90% of cases. Likewise, Dr. Antonio Cubillo, coordinator of Digestive Tumors Unit CIOCC, detailed the numerous strategies, studies and technologies aimed at personalizing treatment of this neoplasm is developing HM hospitals.
Finally, the V Pitched Clara Commemorative Lecture, Prof. Eric Van Cutsem, Director of the Department of Digestive Oncology Cancer Institute Leuven (Belgium), reviewed progress towards the personalized approach of metastatic colorectal cancer and the benefits of a correct therapeutic strategy, in which the patient's medical history, their desires and expectations, the co-morbidities or the presence of altered genes involved.